Bristol-Myers Squibb Company (BMY)

59.49
NYSE
Prev Close 58.25
Day Low/High 58.16 / 59.84
52 Wk Low/High 45.76 / 68.34
Exchange NYSE
Shares Outstanding 2253.93B
Market Cap 131.29B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Elections and Stocks: Party Performance, Predicting and Potential Market Winners

Elections and Stocks: Party Performance, Predicting and Potential Market Winners

The market's performance in the three months leading up to a presidential election has displayed an uncanny ability to forecast which party will win the White House.

Back to Back Wins for Bristol-Myers, and Here's How I'd Trade It

Back to Back Wins for Bristol-Myers, and Here's How I'd Trade It

BMY sees reason for optimism over the final half of the year.

Charting the Dow, Job Creation, Washington Deal or No Deal? Roku's Problem

Charting the Dow, Job Creation, Washington Deal or No Deal? Roku's Problem

Check out the Dow Transports and the Dow Industrials.

7 Drug Stocks With the Right Medicine for Investors

7 Drug Stocks With the Right Medicine for Investors

These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.

Use DRIPs to Build a Socially Responsible Portfolio

Use DRIPs to Build a Socially Responsible Portfolio

Many quality companies that fit into the socially responsible investing camp offer direct-purchase plans, allowing investors an easy way to build an SRI portfolio.

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.

This Chart Pattern Hints at a Bullish Future

This Chart Pattern Hints at a Bullish Future

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

Trading Volume, Late Selloffs, Peloton's Run Higher

Trading Volume, Late Selloffs, Peloton's Run Higher

As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.

Genprex Is Soaring - And There's a One Word Reason Why

Genprex Is Soaring - And There's a One Word Reason Why

The small biotech's market cap sits at $125 million, the low end of what I believe is fair.

Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying

Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying

They buy and buy and buy. The same stocks. Over and over. No end to it.

Jim Cramer: Goodbye to a Horrid Quarter

Jim Cramer: Goodbye to a Horrid Quarter

Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.

Bear Markets Do End, But What Should Investors Be Doing Now?

Bear Markets Do End, But What Should Investors Be Doing Now?

At the end of the day, investors really have only three choices to make when managing an investment portfolio -- buy, hold, or sell.

Three Strategies for Income Investors

Three Strategies for Income Investors

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Watch These Biotech Names on Strong Earnings

Watch These Biotech Names on Strong Earnings

Merger activity is the number 1 driver I am watching for biotech growth.

China Reduces Tariffs, 20 Year Treasury Bonds, Pricey Peloton: Market Recon

China Reduces Tariffs, 20 Year Treasury Bonds, Pricey Peloton: Market Recon

This move by Beijing comes on top of massive injections of liquidity into that nation's financial system earlier this week.

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.

Jim Cramer: Larry Fink Is Showing What True Leadership Looks Like

Jim Cramer: Larry Fink Is Showing What True Leadership Looks Like

BlackRock's CEO will now make investment decisions based on a company's commitment to environmental sustainability. You can bet the financial world will never be the same again.

Jim Cramer: The HQ for Innovation Is Right Here in San Francisco

Jim Cramer: The HQ for Innovation Is Right Here in San Francisco

The NYSE used to be the center of capitalism, but now it's where actual engineering, not financial engineering, is taking place.

Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter

Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter

Let's review the charts.

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

Jim Cramer: Don't Get Sacked in This Political Football Match

Jim Cramer: Don't Get Sacked in This Political Football Match

How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

Bristol-Myers Squibb May Trade Sideways for a Bit but Expect New Highs Later

Bristol-Myers Squibb May Trade Sideways for a Bit but Expect New Highs Later

The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.

3 Boomer-Inspired Drug Plays With Dividend Appeal

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

Jim Cramer: Why Doesn't Impeachment Matter More to the Market?

Jim Cramer: Why Doesn't Impeachment Matter More to the Market?

The impeachment and trial of President Trump has nothing to do with the price to earnings ratio of Bristol-Myers or any other stock for that matter.

3 Biotech Stocks With the Best-Looking Charts

3 Biotech Stocks With the Best-Looking Charts

Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.